[Comment] The ADORE trial results and the ongoing edaravone debate

Author profile image Aggregator
0 comments
Edaravone has been approved in some countries for the treatment of amyotrophic lateral sclerosis, on the basis of a modest slowing of functional decline in a subgroup of patients in a small pivotal trial in Japan.1 In The Lancet Neurology, Ruben van Eijk and colleagues2 report the results of ADORE, a phase 3 randomised controlled trial of oral edaravone (FNP122) in 302 participants with amyotrophic lateral sclerosis. The trial showed no statistically significant difference in the primary outcome (change in amyotrophic lateral sclerosis functional rating scale-revised [ALSFRS-R] total score from baseline to week 48) between the edaravone and placebo groups.

Source: The Lancet Neurology - Current Issue Published 30 Nov 2026 Imported 19 Nov 2026 Relevancy: Not reviewed

Read the article